Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Efficacy of short-course treatment for prevention of congenital transmission of Chagas disease: A retrospective cohort study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
      Chagas Disease*/drug therapy ; Chagas Disease*/prevention & control ; Nitroimidazoles*/therapeutic use ; Trypanosoma cruzi* ; Trypanocidal Agents*/therapeutic use; Infant ; Child ; Infant, Newborn ; Humans ; Female ; Male ; Retrospective Studies ; Infectious Disease Transmission, Vertical/prevention & control ; Nifurtimox/therapeutic use
    • نبذة مختصرة :
      Background: In regions with controlled vector transmission of T. cruzi, congenital transmission is the most frequent route of infection. Treatment with benznidazole (BZ) or nifurtimox (NF) for 60 days in girls and women of childbearing age showed to be effective in preventing mother to child transmission of this disease. Reports on short-course treatment (≤30 days) are scarce.
      Methods: Retrospective cohort study. Offspring of women with Chagas disease who received short-course treatment (≤30 days) with BZ or NF, attended between 2003 and 2022, were evaluated. Parasitemia (microhaematocrit and/or PCR) was performed at <8 months of age, and serology (ELISA and IHA) at ≥8 months to rule out congenital infection.
      Results: A total of 27 women receiving ≤30 days of treatment and their children were included in this study. NF was prescribed in 17/27 (63%) women, and BZ in 10/27 (37%). The mean duration of treatment was 29.2 days. None of the women experienced serious adverse events during treatment, and no laboratory abnormalities were observed. Forty infants born to these 27 treated women were included. All newborns were full term, with appropriate weight for their gestational age. No perinatal infectious diseases or complications were observed.
      Discussion: Several studies have shown that treatment of infected girls and women of childbearing age for 60 days is an effective practice to prevent transplacental transmission of T. cruzi. Our study demonstrated that short-duration treatment (≤30 days) is effective and beneficial in preventing transplacental transmission of Chagas disease.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2024 Moscatelli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Mem Inst Oswaldo Cruz. 2015 Jun;110(4):507-9. (PMID: 25993401)
      PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3312. (PMID: 25411847)
      PLoS Negl Trop Dis. 2021 Jan 7;15(1):e0008912. (PMID: 33412557)
      J Infect Dev Ctries. 2013 Aug 15;7(8):635-7. (PMID: 23949300)
      Clin Infect Dis. 2013 Feb;56(4):496-502. (PMID: 23097582)
      Mol Diagn Ther. 2021 Nov;25(6):791-801. (PMID: 34426953)
      Pediatrics. 2011 Jan;127(1):e212-8. (PMID: 21173000)
      Reprod Health. 2020 Aug 24;17(1):128. (PMID: 32831069)
      Methods Mol Biol. 2019;1955:215-225. (PMID: 30868530)
      Clin Infect Dis. 1995 Sep;21(3):551-5. (PMID: 8527542)
      Lancet Infect Dis. 2021 Aug;21(8):1129-1140. (PMID: 33836161)
      BMJ Open. 2021 Dec 31;11(12):e052897. (PMID: 34972765)
      Emerg Infect Dis. 2013;19(9):1490-2. (PMID: 23965334)
      J Antimicrob Chemother. 2003 Sep;52(3):441-9. (PMID: 12917253)
      PLoS Negl Trop Dis. 2019 Aug 29;13(8):e0007668. (PMID: 31465522)
      Antimicrob Agents Chemother. 2022 May 17;66(5):e0202121. (PMID: 35416710)
      Rev Soc Bras Med Trop. 2009 Sep-Oct;42(5):484-7. (PMID: 19967227)
      BJOG. 2014 Jan;121(1):22-33. (PMID: 23924273)
      Ann Intern Med. 2006 May 16;144(10):724-34. (PMID: 16702588)
    • الرقم المعرف:
      M84I3K7C2O (Nifurtimox)
      YC42NRJ1ZD (benzonidazole)
      0 (Nitroimidazoles)
      0 (Trypanocidal Agents)
    • الموضوع:
      Date Created: 20240122 Date Completed: 20240205 Latest Revision: 20240206
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC10833510
    • الرقم المعرف:
      10.1371/journal.pntd.0011895
    • الرقم المعرف:
      38252673